Loading...
•
Sep 30, 2025
Abbott Q3 2025 Earnings Report
Abbott reported steady growth across key businesses with strong performance in medical devices and reaffirmed full-year guidance.
Key Takeaways
Abbott delivered solid Q3 2025 results with revenue of $11.37B and adjusted EPS of $1.30, driven by growth in Medical Devices and strong momentum in Diabetes Care.
Medical Devices sales rose to $5.45B, with Diabetes Care up over 20% on a reported basis.
Reported EPS was $0.94 and adjusted EPS was $1.30.
Net income came in at $1.644B for the quarter.
COVID-19 testing-related sales dropped significantly YoY to $69M.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Abbott reaffirmed its full-year 2025 guidance for both revenue and adjusted EPS, narrowing its EPS range to $5.12-$5.18.
Positive Outlook
- Full-year organic sales growth guidance reaffirmed at 7.5%-8.0% (excluding COVID-19 testing).
- Adjusted EPS guidance midpoint reaffirmed and narrowed to $5.12-$5.18.
- Diabetes Care continues to show robust growth momentum.
- New product approvals in Japan and Europe support future growth.
- Consistent dividend payouts, now for 407 consecutive quarters.
Challenges Ahead
- Diagnostics segment faced declines due to lower COVID-19 test sales.
- Challenging market conditions in China affected Core Lab growth.
- Diagnostics organic revenue down 7.8% YoY.
- Nutrition U.S. revenue declined by 6.5%.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...